orbofiban has been researched along with Angina, Unstable in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC | 1 |
| Braunwauld, E; Cannon, CP; Cantor, WJ; Charlesworth, A; Goodman, SG; Langer, A; Murphy, SA | 1 |
| Abernethy, DR; Cox, D; Fitzgerald, DJ; Mager, DE; Shirey, JD | 1 |
| Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE | 1 |
| Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM | 1 |
| Alonso Castillejos, N; García Iglesias, R; Inglada-Galiana, L; Martín Gil, FJ; San Miguel Hernández, A | 1 |
| Braunwald, E; Cannon, CP; de Lemos, JA; McCabe, CH; Morrow, DA; Murphy, S; Rifai, N; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| McGuire, DK; Newby, LK | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Cox, D; Crean, P; Fitzgerald, DJ; Quinn, M; Smith, R; Theroux, P | 1 |
| Cannon, CP | 1 |
| Bentley, JH; Braunwald, E; Cannon, CP; McCabe, CH; Wilcox, RG | 1 |
| Anders, R; Burns, D; Kleiman, J; Nicholson, N; Wazowicz, B | 1 |
| Braunwald, E; Cannon, CP; Fitzgerald, A; Fitzgerald, DJ; O'Connor, FF; Shields, DC | 1 |
3 review(s) available for orbofiban and Angina, Unstable
| Article | Year |
|---|---|
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Syndrome; Treatment Outcome | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Drug Therapy, Combination; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2000 |
Xemilofiban/orbofiban: insight into drug development.
Topics: Alanine; Angina, Unstable; Animals; Benzamidines; Bleeding Time; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronary Thrombosis; Drug Evaluation, Preclinical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2001 |
8 trial(s) available for orbofiban and Angina, Unstable
| Article | Year |
|---|---|
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional Studies; Extracellular Matrix; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hemorrhage; Heterozygote; Humans; Minisatellite Repeats; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Treatment Outcome | 2002 |
Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Topics: Aged; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stents; Survival Analysis | 2005 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stroke; Syndrome; Thrombolytic Therapy | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombocytopenia; Thrombosis | 2006 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Risk; Syndrome | 2007 |
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2000 |
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.
Topics: Aged; Alanine; Angina, Unstable; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrrolidines; Risk Factors; Survival Rate | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines | 2001 |
3 other study(ies) available for orbofiban and Angina, Unstable
| Article | Year |
|---|---|
Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
Topics: Alanine; Angina, Unstable; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Neural Networks, Computer; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Reproducibility of Results | 2005 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherosclerosis; Biomarkers; Cardiovascular Diseases; CD40 Ligand; Chromosomes, Human, X; Clinical Trials as Topic; Disease Models, Animal; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Mice; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Pyrrolidines; Risk Factors; Thrombosis | 2007 |
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Topics: Alanine; Angina, Unstable; Benzamidines; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome | 2000 |